Clinical Trial: A Randomized, Double-blind, Placebo-controlled Proof-of-concept Study of EI-001 in Non-segmental Vitiligo Patients

U.S., Nov. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07223229) titled 'A Randomized, Double-blind, Placebo-controlled Proof-of-concept Study of EI-001 in Non-segmental Vitiligo Patients' on Oct. 29.

Brief Summary: The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.

Study Start Date: Dec. 30

Study Type: INTERVENTIONAL

Con...